130 related articles for article (PubMed ID: 16549810)
1. Oxaliplatin-related acute myelogenous leukemia.
Carneiro BA; Kaminer L; Eldibany M; Sreekantaiah C; Kaul K; Locker GY
Oncologist; 2006 Mar; 11(3):261-2. PubMed ID: 16549810
[TBL] [Abstract][Full Text] [Related]
2. [A case successfully treated with total pelvic exenteration after preoperative chemotherapy FOLFOX4 plus bevacizumab for unresectable sigmoid colon cancer with extramural progression].
Yasue H; Hanyu N; Usuba T; Abe M
Gan To Kagaku Ryoho; 2010 Feb; 37(2):327-9. PubMed ID: 20154496
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
5. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Vaidyanathan G; Groman A; Wilding G; Fakih MG
Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
7. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
Tyagi P; Grothey A
Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
9. Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer.
Merlin F; Prochilo T; Kildani B; Tucci A; Ferrari S; Rossi G; D'Adda P; Beretta GD
Acta Oncol; 2008; 47(3):464-6. PubMed ID: 17851873
[No Abstract] [Full Text] [Related]
10. [Ovarian metastasis after complete response of colon cancer].
Nishimura T; Maeda Y; Okada T; Nakamura M; Sakata K; Setoguchi M; Kawasaki N
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2263-5. PubMed ID: 20037390
[TBL] [Abstract][Full Text] [Related]
11. [A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
Tamura T; Ishikawa N; Koui S; Nakashima H; Minagawa N; Hachiya Y; Hirata K; Sako T; Fukuyama T; Hirano Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1813-6. PubMed ID: 20841954
[TBL] [Abstract][Full Text] [Related]
12. A case of 5-fluorouracil-induced acute psychosis.
Fora A; Alabsi E; Fakih M
Clin Colorectal Cancer; 2009 Jul; 8(3):166-8. PubMed ID: 19632932
[TBL] [Abstract][Full Text] [Related]
13. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
14. [A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].
Honda K; Hata Y; Ihara E; Tomita Y; Miyata S; Sumida Y; Ihara Y; Misawa T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1533-6. PubMed ID: 21918357
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
Xiang XJ; Liu YW; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
Anticancer Drugs; 2012 Jun; 23(5):561-6. PubMed ID: 22481063
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
19. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
[No Abstract] [Full Text] [Related]
20. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
